Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

438P - Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma


22 Nov 2020


e-Poster Display Session


Tumour Site



Carolina Ortiz Velez


Annals of Oncology (2020) 31 (suppl_6): S1407-S1415. 10.1016/annonc/annonc368


C. Ortiz Velez1, G. Villacampa Javierre2, E. Zamora1, A. Garcia Alvarez3, D.G. Illescas3, C. Viaplana2, M. Batista4, M. Martinez4, V. Garcia-Patos5, D. Bodet-Castillo5, B. Ferrer Fabregas6, J.A. Recio7, J. Hernandez Losa6, X. Villalobos Alberú8, R. Dienstmann2, E. Muñoz-Couselo1

Author affiliations

  • 1 Breast Cancer And Melanoma Dept., Vall d`Hebron University Hospital Institut d'Oncologia, 8035 - Barcelona/ES
  • 2 Oncology Data Science (odyssey) Group, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES
  • 3 Medical Oncology, Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 4 Study Coordinator, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES
  • 5 Department Of Dermatology, Vall d`Hebron University Hospital Institut d'Oncologia, 8035 - Barcelona/ES
  • 6 Department Of Pathology, Vall d`Hebron University Hospital Institut d'Oncologia, 8035 - Barcelona/ES
  • 7 Melanoma Clinical Research Group, Vall d`Hebron University Hospital Institut d'Oncologia, 8035 - Barcelona/ES
  • 8 Project Manager, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 438P


Adjuvant (adj) Tx with programmed cell death protein 1 (PD-1) inhibitors or targeted therapy (TT) for 1 year in patients (pts) with high-risk resected melanoma prolongs relapse-free survival (RFS). However, up to 1/3 of pts recur in the year after adj Tx and there are few data regarding patterns of relapse, management and outcomes. Our aim was to describe how adj Tx impacts the outcomes in melanoma pts in our center.


Single-institution experience of 123 consecutive pts with melanoma resected in our center from 2014 to 2019 were retrospectively analyzed. Clinicopathological factors, adj Tx, timing and patterns of relapse, Tx at relapse and subsequent outcomes were examined.


Median age at diagnosis was 57 years, 45% were male and BRAF-mt was found in 38%. Stage III A/B/C/D or IV was 6%, 10%, 19%, 1% and 1%, respectively. Sentinel node biopsy was performed in 80% and lymphadenectomy in 33% of 123 pts. A total of 49 pts received adj Tx: 3 pts (6%) TT, 8 pts (16%) IFN-α, and 38 pts (31%) immunotherapy (iTx) with anti-PD-1 and/or ipilimumab. A total of 40 pts (32%) had relapse (65% locoregional and 35% distant), 8 pts (21%) had prior adj iTx with a median RFS of 21.5 months (m) (CI95%17.4-NA). 24 pts (60%) were resected (6 pts with distant recurrent), 14 pts received adj Tx (12 pts iTx, 1 pt IFN-α and 1 pt TT), for 4-pts was the second adj Tx. A total of 31 of 123 pts (25%) developed metastatic melanoma (MM), of these 17 pts (55%) received adj Tx. PFS at 1st line of Tx of pts with prior adj-Tx vs no was similar (HR=1.01, p=0.98), mainly Tx were iTx (65%), TT (31%) and chemotherapy (4%). Remarkably, there was no worse response rate (complete response [CR] or partial response [PR]) in pts with prior adj Tx (68.8% vs 35.7%, p=0.14). Of 17 pts with prior adj-Tx (16 pts adj-iTx) who had MM, twelve (70.6%) received iTx at 1st line, 50% had response to iTx. Also, all 4 pts BRAF-mt with prior adj iTx who received TT at 1st line had CR or PR. There was no correlation between treatment-free interval after adj TX and PFS at 1st line (p=0.66).


Our real-world data demonstrates that after a locoregional or distant relapse of melanoma, despite prior adj-Tx, Tx with iTx or TT can be active. But additional research is needed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


R. Dienstmann: Advisory/Consultancy: Roche, Boehringer Ingelheim; Honoraria (self): Roche, Ipsen, Amgen, Servier, Sanofi, Merck Sharp & Dohme; Research grant/Funding (self): Merck, Pierre Fabre. E. Muñoz-Couselo: Advisory/Consultancy: BMS; Advisory/Consultancy: Novartis; Advisory/Consultancy: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.